Perspective Therapeutics, Inc.
AMEX:CATXMedical - Devices
+$0.02 today
- Market cap
- $94.20M
- Beta
- 1.73
- P/E (TTM)
- -0.0
- EPS (TTM)
- -$107.27
Volume 2.69M
Average 1.44M
CATX Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Perspective Therapeutics, Inc.AMEX: CATX
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures growth accelerates
Q1 FY2026 capital expenditures of $6.86M (cash outflow) rose 47.3% year over year, ahead of the -70.1% change in trailing-twelve-month capital expenditures. Sequentially, it rose 35.1% from the prior quarter. Over 3 fiscal years it compounded at +248.2% a year.
Context
- Capital expenditures amounted to 1442.2% of revenue in FY2025, down 2300.2 pp from a year earlier.
- Capital expenditures grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +47.3% holds above the trailing-twelve-month pace of -70.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (12.75M) USD
- Year-over-year change
- +76.6%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (12.75M) | +76.6% |
| FY2024 | 2024-12-31 | (54.41M) | -4975.9% |
| FY2023 | 2023-12-31 | (1.07M) | -255.0% |
| FY2022 | 2022-12-31 | (302K) | -13.5% |
| FY2021 | 2022-06-30 | (266K) | — |
Capital Expenditures vs competitors
How CATX compares with its peers on the latest reported figures
- CATX's LTM Mar 2026 capital expenditures of $14.95M is the 2nd largest of the 5 companies compared; the peer median is $1.14M.
- Its year-over-year change of -70.1% is the 4th highest of 5, against a peer median of +69.5%.
- Capital expenditures amounts to 2419.3% of revenue for CATX, versus a peer median of 1.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $21.19M | -49.2% | +7.7% | 3.1% | |
| LTM Mar 2026 | $14.95M | -70.1% | +248.2% | 2419.3% | |
| LTM Mar 2026 | $1.98M | +188.2% | +94.9% | 2.2% | |
| LTM Mar 2026 | $305K | -70.5% | +5.3% | 0.7% | |
| LTM Mar 2026 | $192K | +284.0% | +7.2% | 0.9% | |
| Peer median (excluding CATX) | $1.14M | +69.5% | +7.4% | 1.5% | |
Competitors are the stored peer set for CATX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Jun 2022 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (7.27M) | (14.67M) | (46.51M) | (79.28M) | (103.12M) |
| Depreciation & Amortization | 248K | 344K | 946K | 2.31M | 3.25M |
| Deferred Income Tax | 0 | (1.68M) | (2.65M) | (2.1M) | (793K) |
| Stock-Based Compensation | 1.09M | 1.34M | 3.74M | 5.39M | 8.97M |
| Change in Working Capital | (1.85M) | 338K | 2.3M | 31.81M | 1.68M |
| Accounts Receivables | 405K | 490K | (426K) | 1.05M | (32K) |
| Inventory | (2.67M) | (152K) | 359K | 11K | 0 |
| Accounts Payables | 236K | 0 | 1.58M | 1.89M | 147K |
| Other Working Capital | 182K | (28K) | 779K | 29.74M | 1.57M |
| Other Non-Cash Items | 77K | 472K | 5.27M | 55.39M | 7.53M |
| Operating Cash Flow | (7.71M) | (12.17M) | (36.91M) | (18.29M) | (82.48M) |
| Capital Expenditures | (266K) | (302K) | (1.07M) | (54.41M) | (12.75M) |
| Acquisitions (Net) | 0 | 0 | 2.7M | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (243.51M) | (119.84M) |
| Sales of Investments | 0 | 0 | 22.76M | 0 | 173.95M |
| Other Investing Activities | (18K) | (57.38M) | (18K) | 78.99M | (135K) |
| Investing Cash Flow | (284K) | (57.68M) | 24.37M | (218.93M) | 41.23M |
| Debt Repayment | — | — | (68K) | (48K) | (52K) |
| Common Stock Issued | 56K | 0 | 364K | 275.81M | 10.36M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 56K | 489K | 289.39M | 0 |
| Financing Cash Flow | 56K | 56K | 785K | 289.39M | 10.31M |
| Effect of Forex Changes | 0 | 61.86M | 0 | 0 | 0 |
| Net Change in Cash | (7.94M) | 182K | (46.65M) | 52.16M | (30.95M) |
| Free Cash Flow | (7.98M) | (12.47M) | (37.99M) | (72.71M) | (95.23M) |
Perspective Therapeutics, Inc.
AMEX:CATX
Intrinsic Alpha fair value
Locked
Current Price
$0.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.